Boehringer's nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
FIBRONEER™-IPF trial met primary endpoint: absolute change in Forced Vital Capacity at week 52. Boehringer Ingelheim to submit nerandomilast for IPF treatment to FDA and other Health Authorities worldwide.
Related Clinical Trials
Reference News
Boehringer's nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
FIBRONEER™-IPF trial met primary endpoint: absolute change in Forced Vital Capacity at week 52. Boehringer Ingelheim to submit nerandomilast for IPF treatment to FDA and other Health Authorities worldwide.